Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
BO
Boundless Bio, Inc. Common Stock
BOLD
Mkt Cap
$54.0M
Volume
692.78K
Next Earnings
November 4th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
BO
BOLD
BO
Boundless Bio, Inc. Common Stock
BOLD
News
·
Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting
Mkt Cap
$54.1M
Volume
692.78K
Next Earnings
November 4th
Chart
Financials
Earnings
News
About
Insider
Filings
Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting
Boundless Bio presented preclinical data supporting BBI-940, an oral kinesin degrader, as a potential first-in-class therapy for advanced or metastatic breast cancers. The compound targets a novel kinesin protein essential for extrachromosomal DNA (ecDNA) segregation in cancer cells but non-essential in healthy cells. Preclinical studies demonstrated tumor regressions in ecDNA-positive breast cancer models, with the Phase 1 KOMODO-1 clinical trial currently enrolling patients with ER+/HER2- and TNBC-LAR breast cancers.
GlobeNewswire Inc. · Apr 17, 2026
Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Boundless Bio announced financial results for 2025 with $107.6 million in cash providing runway through mid-2028. The company's lead program BBI-940, a first-in-class oral Kinesin degrader, is actively enrolling patients in the KOMODO-1 trial for ER+/HER2- breast cancer and TNBC-LAR. The company reduced R&D expenses to $44.8 million for 2025 and narrowed net losses to $58.2 million. Boundless ceased enrollment in the POTENTIATE trial to prioritize BBI-940 development.
GlobeNewswire Inc. · Mar 9, 2026
Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Boundless Bio announced that its novel Kinesin degrader BBI-940 received IND acceptance, with first-in-human clinical trials expected to begin in the first half of 2026. The company extended its operating runway through portfolio prioritization, including discontinuation of the POTENTIATE trial. CEO Zachary Hornby will participate in upcoming biotech industry conferences.
GlobeNewswire Inc. · Feb 5, 2026
Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights
Boundless Bio, a clinical-stage oncology company, reported its Q1 2025 financial results and provided updates on its pipeline. The company has a cash position of $138.3 million, which is expected to fund operations into 2027. Boundless Bio is advancing its BBI-355 program, a CHK1 inhibitor, and its novel Kinesin program, with key milestones expected in 2025 and 2026.
GlobeNewswire Inc. · May 9, 2025
Boundless Bio to Participate in the Needham Virtual Healthcare Conference
Boundless Bio, a clinical-stage oncology company, announced that its President and CEO will participate in Needham's Virtual Healthcare Conference. The company is developing an oral inhibitor of checkpoint kinase 1 (CHK1) to target extrachromosomal DNA (ecDNA) in oncogene amplified cancers.
GlobeNewswire Inc. · Apr 3, 2025
Boundless Bio to Participate in the 2024 Cantor Global Healthcare Conference
Boundless Bio, a clinical-stage oncology company, announced that its executives will participate in the 2024 Cantor Global Healthcare Conference. The company is developing therapies targeting extrachromosomal DNA (ecDNA) to treat oncogene amplified cancers.
GlobeNewswire Inc. · Sep 11, 2024
Wall Street Breakfast: The Week Ahead
Stay updated with the latest financial news and market trends by listening to the Wall Street Breakfast podcast available on Seeking Alpha, iTunes, and...
Seeking Alpha · Apr 21, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
BO
BOLD
Boundless Bio, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
BOLD
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any BOLD yet.
Related Tickers
Earnings